Ride Health Raises $10 Million to Scale National Medical Transportation Platform
Company brings real-time visibility to the non-emergency medical transportation industry, improving access to care and social resources for underserved populations
Ride Health Raises $10 Million to Scale National Medical Transportation Platform
Company brings real-time visibility to the non-emergency medical transportation industry, improving access to care and social resources for underserved populations
InfraScan Inc. Announces DoD/DHA Product Development Partnership
InfraScan announces product development partnership with DoD
Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors
– Dr. Prendergast is a renowned scientific researcher with over 45 years of association with the Mayo Foundation and over 20 years’ experience as a non-executive director of Eli Lilly
Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies
A highly potent panel of VNARs against the SARS-CoV-2 spike protein has been isolated
Neutralization of SARS-CoV-2 was demonstrated in in vitro infectivity assays
In vitro blocking activities were also found against the N501Y and E484K mutants
Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics
Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer
Former chief medical officer of MyoKardia to lead clinical development at Renovacor
Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern
– Additional $4.3 million in funding brings total DOD funding to $17.6 million.
– Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.
– Neutralizes South Africa (B.1.351) and UK (B.1.1.7) in live virus testing and Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are CDC-designated “Variants of Concern.”
– Binds to several mutations, including E484Q and L452R, which are associated with the India variant (B.1.617) in mechanistic testing.